Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Clin Cancer Res. 2019 Aug 1;25(21):6532–6545. doi: 10.1158/1078-0432.CCR-19-0498

Fig. 1. POU-domain TFs BRN1 and BRN4 are highly expressed in neuroendocrine PCa cell line models and enzalutamide resistant cells.

Fig. 1

A. Genomic alterations in Class III POU-domain genes in prostate neuroendocrine carcinomas (CRPC-NE), mixed small cell carcinoma-adenocarcinomas and adenocarcinomas in SUC2C/PCF Dream Team (38) and Beltran et al (11) cohorts as analyzed by cBioPortal. Lower panel shows the relative frequencies of these alterations in PRAD, CRPC and NEPC cases within these two cohorts.

B. Correlation analyses of BRN1, BRN2 and BRN4 mRNA and CNAs in the two cohorts.

C. Relative mRNA levels of BRN1, BRN2 and BRN4 in normal immortalized prostate epithelial cell line (RWPE-1), benign non-transformed prostate epithelial cell line (BPH1) and PCa cell lines (PC3, Du145, LNCaP and NCI-H660) as assessed by real-time PCR. Data were normalized to GAPDH control and represented as mean ± SEM.

D. Relative mRNA levels of BRN11, BRN2 and BRN4 in LNCaP cells cultured in regular media (control), androgen-depleted media (C/D FBS) and 20 µM ENZ in C/D FBS media as assessed by real-time PCR. Data were normalized to GAPDH control and represented as mean ± SEM.

E. Left panel: Relative mRNA levels of BRN1, BRN2 and BRN4 in LNCaP, LNCaP-AR and ENZ-resistant LNCaP-AR cells as assessed by real-time PCR. Data were normalized to GAPDH control and represented as mean ± SEM. Right panel: Western blot analyses of BRN4, BRN2 and indicated neuronal markers in LNCaP, LNCaP-AR and ENZ-resistant LNCaP-AR cells. GAPDH was used as a loading control.